That is allowing availability of drugs to increase in poor countries. The real challenge now is how exactly we get enough cash to keep and grow treatment access in all countries. Addititionally there is the challenge of making sure people stay on the treatments forever. They are both what the implementation is called by us challenges. The scientific challenges are finding a vaccine and a cure. We really need both of these in order to see the final end of AIDS. Where can visitors find more information? has some great information, including video clips, webcasts, summaries of the sessions and so forth. About Professor Sharon Lewin Professor Lewin is an infectious diseases physician and basic scientist.Abstracts from the meeting will be accessible online on November 7, 2011 conference. With this trial enrolled and all sufferers evaluable fully, data showed a continuing improvement as time passes in the anti-leukemic activity and response prices among individuals with chronic-stage CML treated with ponatinib. Further, there were no treatment discontinuations or loss of a significant cytogenetic response among chronic-phase individuals in the analysis because the prior data upgrade on the trial in December, 2010. At the proper time of the most recent analysis, the length of response to ponatinib ranged from 58 to 820 days . The median duration of ponatinib response has not yet been reached among chronic-phase sufferers in this trial.